ESMO Asia 2025 | How will second-line tarlatamab improve outcomes in ES-SCLC?
Surein Arulananda, MBBS, PhD, Monash Health, Melbourne, Australia, describes the significance of the DeLLphi-304 trial (NCT05740566), which demonstrated the superiority of tarlatamab over second-line chemotherapy in terms of overall survival in patients with extensive stage small cell lung cancer (ES-SCLC). Tarlatamab has established itself in the second-line setting for these patients and is likely to be moved to an earlier line setting once ongoing phase three trials are completed. This interview took place at 2025 European Society for Medical Oncology (ESMO) Asia Congress in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So DeLLphi-304 was really quite a remarkable trial because for the first time in history, really, in a phase three context, we saw a drug beat out second line chemotherapy in terms of overall survival. And with the additional benefit of having less AEs really compared to the second line chemotherapy. So tarlatamab has very much entrenched itself in the second line setting of patients with extensive stage small cell lung cancer who have progressed on platinum doublet chemotherapy with or without an immune checkpoint inhibitor...
So DeLLphi-304 was really quite a remarkable trial because for the first time in history, really, in a phase three context, we saw a drug beat out second line chemotherapy in terms of overall survival. And with the additional benefit of having less AEs really compared to the second line chemotherapy. So tarlatamab has very much entrenched itself in the second line setting of patients with extensive stage small cell lung cancer who have progressed on platinum doublet chemotherapy with or without an immune checkpoint inhibitor. In fact, it is almost certainly going to be moved into the earlier line setting once those phase three trials are done.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
